NHS Midland & East Branded Medicines, Tranche B & Annual Tranche

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
2 year
Value
£480M
Sector
HEALTH
Published
15 Mar 2023
Delivery
01 Mar 2023 to 28 Feb 2025
Deadline
25 Oct 2022 12:00

Concepts

Location

Geochart for 1 buyers and 35 suppliers

1 buyer

35 suppliers

Description

NHS Framework for Midlands and East Branded Medicines - Tranche B and Annual Tranche. Offer reference number: CM/PHR/20/5608 CM/PHR/20/5608/01 - NHS Framework for Midlands and East Branded Medicines - Tranche B. Period of framework: 1 March 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/20/5608/02 - NHS Framework for Midlands and East Branded Medicines - Annual Tranche. Period of framework: 1 March 2023 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Award Detail

1 Sandoz (Camberley)
  • Value: £480,429,000
2 Teva (Castleford)
  • Value: £480,429,000
3 Roche Products (Welwyn Garden City)
  • Value: £480,429,000
4 Kent Pharma (Ashford)
  • Value: £480,429,000
5 Ul Global Pharma (Hemel Hempstead)
  • Value: £480,429,000
6 Celltrion Healthcare (Slough)
  • Value: £480,429,000
7 Merck Sharpe & Dohme (London)
  • Value: £480,429,000
8 Amgen (Cambridge)
  • Value: £480,429,000
9 Mylan (Potters Bar)
  • Value: £480,429,000
10 Thornton & Ross (Huddersfield)
  • Value: £480,429,000
11 Janssen Cilag (Highwycombe)
  • Value: £480,429,000
12 Bayer (Reading)
  • Value: £480,429,000
13 Accord (Barnstaple)
  • Value: £480,429,000
14 Pfizer (Sandwich)
  • Value: £480,429,000
15 Glaxosmithkline (London)
  • Value: £480,429,000
16 Abbvie (Maidenhead)
  • Value: £480,429,000
17 Neon Healthcare (Hertford)
  • Value: £480,429,000
18 Astrazeneca (London)
  • Value: £480,429,000
19 Aventis Pharma (Reading)
  • Value: £480,429,000
20 Ipsen (Slough)
  • Value: £480,429,000
21 Biogen (Maidenhead)
  • Value: £480,429,000
22 Takeda (London)
  • Value: £480,429,000
23 Merck Serono (Feltham)
  • Value: £480,429,000
24 Organon Pharmaceuticals (London)
  • Value: £480,429,000
25 Zentiva Pharma (London)
  • Value: £480,429,000
26 Novo Nordisk (Gatwick)
  • Value: £480,429,000
27 Novartis Pharmaceuticals (London)
  • Value: £480,429,000
28 Eli Lilly (Hants)
  • Value: £480,429,000
29 CST Pharma (Walsall)
  • Value: £480,429,000
30 Gilead Sciences (London)
  • Value: £480,429,000
31 Gedeon Richter (London)
  • Value: £480,429,000
32 Sobi Swedish Orphan Biovitrum (Great Abington)
  • Value: £480,429,000
33 Almirall (Uxbridge)
  • Value: £480,429,000
34 Typharm (Norwich)
  • Value: £480,429,000
35 Ucb Pharma (Slough)
  • Value: £480,429,000

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

5608 01 Transparency Award Schedule 5608 01 Transparency Award Schedule.pdf 5608 02 Transparency Award Schedule 2 5608 02 Transparency Award Schedule 2.pdf Document No. 03 - Framework Agreement and Terms and Conditions Document No. 03 - Framework Agreement and Terms and Conditions.docx Document No. 10 - Participating authorities Document No. 10 - Participating authorities.xls FTS OPPORTUNITY NOTICE - 2022S 000-026739 CM-PHR-20-5608 - NHS Framework for Midlands and East Branded Medicines - Tranche B FTS OPPORTUNITY NOTICE - 2022S 000-026739 CM-PHR-20-5608 - NHS Framework for Midlands and East Branded Medicines - Tranche B.pdf Parties Appointed to the Framework Agreement - CM_PHR_20_5608 Midlands and East Parties Appointed to the Framework Agreement - CM_PHR_20_5608 Midlands and East.xlsx

Reference

Domains